BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 30988617)

  • 1. Psoralen-loaded lipid-polymer hybrid nanoparticles enhance doxorubicin efficacy in multidrug-resistant HepG2 cells.
    Yuan Y; Cai T; Callaghan R; Li Q; Huang Y; Wang B; Huang Q; Du M; Ma Q; Chiba P; Cai Y
    Int J Nanomedicine; 2019; 14():2207-2218. PubMed ID: 30988617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fabrication of psoralen-loaded lipid-polymer hybrid nanoparticles and their reversal effect on drug resistance of cancer cells.
    Yuan Y; Chiba P; Cai T; Callaghan R; Bai L; Cole SPC; Cai Y
    Oncol Rep; 2018 Aug; 40(2):1055-1063. PubMed ID: 29901161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preparation of psoralen polymer-lipid hybrid nanoparticles and their reversal of multidrug resistance in MCF-7/ADR cells.
    Huang Q; Cai T; Li Q; Huang Y; Liu Q; Wang B; Xia X; Wang Q; Whitney JCC; Cole SPC; Cai Y
    Drug Deliv; 2018 Nov; 25(1):1056-1066. PubMed ID: 29695174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening of metabolites in the treatment of liver cancer xenografts HepG2/ADR by psoralen-loaded lipid nanoparticles.
    Li L; Zou T; Liang M; Mezhuev Y; Tsatsakis AM; Đorđević AB; Lan M; Liu F; Cai T; Gong P; Cai Y
    Eur J Pharm Biopharm; 2021 Aug; 165():337-344. PubMed ID: 34062256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-delivery of paclitaxel and tetrandrine via iRGD peptide conjugated lipid-polymer hybrid nanoparticles overcome multidrug resistance in cancer cells.
    Zhang J; Wang L; Fai Chan H; Xie W; Chen S; He C; Wang Y; Chen M
    Sci Rep; 2017 May; 7():46057. PubMed ID: 28470171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surfactin-based nanoparticles loaded with doxorubicin to overcome multidrug resistance in cancers.
    Huang W; Lang Y; Hakeem A; Lei Y; Gan L; Yang X
    Int J Nanomedicine; 2018; 13():1723-1736. PubMed ID: 29606866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effective combination therapy against human osteosarcoma: doxorubicin plus curcumin co-encapsulated lipid-coated polymeric nanoparticulate drug delivery system.
    Wang L; Wang W; Rui Z; Zhou D
    Drug Deliv; 2016 Nov; 23(9):3200-3208. PubMed ID: 26987435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ROS and GSH-responsive S-nitrosoglutathione functionalized polymeric nanoparticles to overcome multidrug resistance in cancer.
    Wu W; Chen M; Luo T; Fan Y; Zhang J; Zhang Y; Zhang Q; Sapin-Minet A; Gaucher C; Xia X
    Acta Biomater; 2020 Feb; 103():259-271. PubMed ID: 31846803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversal of multidrug resistance in leukemia cells using a transferrin-modified nanomicelle encapsulating both doxorubicin and psoralen.
    Wang HW; Ma KL; Liu H; Zhou JY
    Aging (Albany NY); 2020 Apr; 12(7):6018-6029. PubMed ID: 32259795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced Reactive Oxygen Species Generation by Mitochondria Targeting of Anticancer Drug To Overcome Tumor Multidrug Resistance.
    Liu Y; Zhou Z; Lin X; Xiong X; Zhou R; Zhou M; Huang Y
    Biomacromolecules; 2019 Oct; 20(10):3755-3766. PubMed ID: 31465208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel transferrin modified and doxorubicin loaded Pluronic 85/lipid-polymeric nanoparticles for the treatment of leukemia: In vitro and in vivo therapeutic effect evaluation.
    Zhu B; Zhang H; Yu L
    Biomed Pharmacother; 2017 Feb; 86():547-554. PubMed ID: 28024291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymer-lipid hybrid nanoparticles: A novel drug delivery system for enhancing the activity of Psoralen against breast cancer.
    Du M; Ouyang Y; Meng F; Zhang X; Ma Q; Zhuang Y; Liu H; Pang M; Cai T; Cai Y
    Int J Pharm; 2019 Apr; 561():274-282. PubMed ID: 30851393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delivery of miR-375 and doxorubicin hydrochloride by lipid-coated hollow mesoporous silica nanoparticles to overcome multiple drug resistance in hepatocellular carcinoma.
    Xue H; Yu Z; Liu Y; Yuan W; Yang T; You J; He X; Lee RJ; Li L; Xu C
    Int J Nanomedicine; 2017; 12():5271-5287. PubMed ID: 28769563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The carotenoid fucoxanthin can sensitize multidrug resistant cancer cells to doxorubicin via induction of apoptosis, inhibition of multidrug resistance proteins and metabolic enzymes.
    Eid SY; Althubiti MA; Abdallah ME; Wink M; El-Readi MZ
    Phytomedicine; 2020 Oct; 77():153280. PubMed ID: 32712543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional Doxorubicin-Loaded Omega-3 Unsaturated Fatty Acids Nanoparticles in Reversing Hepatocellular Carcinoma Multidrug Resistance.
    Wang C; Wei X; Shao G
    Med Sci Monit; 2021 Feb; 27():e927727. PubMed ID: 33524008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversing Multidrug Resistance in Chemo-resistant Human Lung Adenocarcinoma (A549/DOX) Cells by Algerian Propolis Through Direct Inhibiting the P-gp Efflux-pump, G0/G1 Cell Cycle Arrest and Apoptosis Induction.
    Kebsa W; Lahouel M; Rouibah H; Zihlif M; Ahram M; Abu-Irmaileh B; Mustafa E; Al-Ameer HJ; Al Shhab M
    Anticancer Agents Med Chem; 2018; 18(9):1330-1337. PubMed ID: 30088453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer.
    Wong HL; Bendayan R; Rauth AM; Wu XY
    J Control Release; 2006 Dec; 116(3):275-84. PubMed ID: 17097178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psoralen reverses the P-glycoprotein-mediated multidrug resistance in human breast cancer MCF-7/ADR cells.
    Jiang J; Wang X; Cheng K; Zhao W; Hua Y; Xu C; Yang Z
    Mol Med Rep; 2016 Jun; 13(6):4745-50. PubMed ID: 27082231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biofunctionalized polymer-lipid supported mesoporous silica nanoparticles for release of chemotherapeutics in multidrug resistant cancer cells.
    Zhang X; Li F; Guo S; Chen X; Wang X; Li J; Gan Y
    Biomaterials; 2014 Apr; 35(11):3650-65. PubMed ID: 24462359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP.
    Dong X; Mattingly CA; Tseng MT; Cho MJ; Liu Y; Adams VR; Mumper RJ
    Cancer Res; 2009 May; 69(9):3918-26. PubMed ID: 19383919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.